Natpar (parathyroid hormone)
OrphanConditionalAdditional monitoring
- Region
- 🇪🇺 EU
- Active substance
- parathyroid hormone
- Company
- Takeda Pharmaceuticals International AG Ireland Branch
- Status
- Withdrawn
- Therapeutic area
- Hypoparathyroidism
- CHMP opinion
- Thu 23 Feb 2017
- EU approval
- Mon 24 Apr 2017
- Designations
- Orphan, Conditional, Additional monitoring
- Application
- EMEA/H/C/003861
- ATC
- H05AA03
- Official record
- www.ema.europa.eu
Indication
Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
Regulatory milestones
Wed 09 Sep 2026🇪🇺 EU shortage
Natpar: medicine discontinued
Powder and solvent for solution for injection; Alternatives available: Yes · source
Same substance in other markets
- 🇪🇺 Preotact Withdrawn · NPS Pharma Holdings Limited
Follow Natpar
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.